TORONTO, Ontario – September 12, 2006: NeuroMedix Inc. (“NeuroMedix”) (TSXV: NMX) today announced that it has completed maximum tolerated dose (“MTD”) studies in two species of animals for Minozac, its lead drug candidate for the treatment of Alzheimer’s disease. The MTD studies were completed in two species of animal and have defined the MTD of the compound based on oral dosing to be in excess of 40 times the therapeutic dose used in a mouse model of Alzheimer’s disease. The results demonstrate that Minozac has no obvious side-effects that might limit its therapeutic use in human patients. The MTD results will be used to select a starting dose for longer-term 28-day repeat dose studies as well as in additional safety pharmacology studies.

“The completion of these MTD studies represents a key milestone in the completion of pre-clinical toxicology studies for Minozac and brings NeuroMedix one step closer to the initiation of a Phase I clinical trial”, said Mark L. Pearson, Chief Executive Officer of NeuroMedix. “The next steps in the development program for Minozac will be longer range toxicity studies”.

NeuroMedix has extended the initial observations made on Minozac at the Center for Drug Discovery and Chemical Biology, Northwestern University and has now completed many of the pre-clinical studies necessary to support an application for a Phase I study. These include detailed genotoxicology, metabolism, and pharmacokinetics studies. The results of these studies show that Minozac has insignificant metabolism by human hepatocytes, no apparent genotoxicity in the Ames assay, and no significant inhibition of CYP 3A4 or other major drug-metabolizing liver enzymes known to alter many therapeutic drugs causing patient-to-patient variation in drug sensitivity.

Additional pre-clinical toxicology and safety pharmacology studies to support oral dosing in humans with Minozac are currently underway. Following successful completion of these enabling pre-clinical studies, NeuroMedix intends to submit a regulatory filing for the initiation of a Phase I clinical trial by the end of calendar 2006.

Minozac, NeuroMedix’s lead compound, acts to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. It has also been shown to reduce inflammation and prevent loss of cognitive function in mice suffering traumatic brain injury.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer’s disease, traumatic brain injury, neuropathic pain, age-related macular degeneration and multiple sclerosis. Our therapeutic drug candidates are based on research from a team of leading experts in the field of neuroinflammation at Northwestern University and have been demonstrated to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. Our lead candidate, Minozac has also been shown to reduce inflammation and prevent loss of cognitive function in mice suffering traumatic brain injury. Based on these findings, NeuroMedix is pursuing the development of its lead compound for Alzheimer’s disease and traumatic brain injury in humans. NeuroMedix’s shares are listed on the TSX Venture Exchange under the symbol “NMX”.

For further information visit www.neuromedixinc.com or contact:

Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
425-503-5156
mark@neuromedixinc.com

or

Catherine Auld, CA
Chief Financial Officer
NeuroMedix Inc.
416-673-8190
cathy@neuromedixinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.